BR112013003847A8 - métodos de tratar a deterioração cognitiva moderada (mci) e os distúrbios relacionados - Google Patents
métodos de tratar a deterioração cognitiva moderada (mci) e os distúrbios relacionadosInfo
- Publication number
- BR112013003847A8 BR112013003847A8 BR112013003847A BR112013003847A BR112013003847A8 BR 112013003847 A8 BR112013003847 A8 BR 112013003847A8 BR 112013003847 A BR112013003847 A BR 112013003847A BR 112013003847 A BR112013003847 A BR 112013003847A BR 112013003847 A8 BR112013003847 A8 BR 112013003847A8
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- mci
- cognitive impairment
- treating moderate
- related disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40190710P | 2010-08-19 | 2010-08-19 | |
| PCT/US2011/048472 WO2012024616A1 (en) | 2010-08-19 | 2011-08-19 | Methods of treating miild cognitive impairment (mci) and related discorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112013003847A2 BR112013003847A2 (pt) | 2016-05-31 |
| BR112013003847A8 true BR112013003847A8 (pt) | 2017-12-26 |
Family
ID=45605447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013003847A BR112013003847A8 (pt) | 2010-08-19 | 2011-08-19 | métodos de tratar a deterioração cognitiva moderada (mci) e os distúrbios relacionados |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10449177B2 (https=) |
| EP (1) | EP2605655B1 (https=) |
| JP (2) | JP6250394B2 (https=) |
| AU (1) | AU2011291506B2 (https=) |
| BR (1) | BR112013003847A8 (https=) |
| CA (1) | CA2808630A1 (https=) |
| DK (1) | DK2605655T3 (https=) |
| ES (1) | ES2705027T3 (https=) |
| MX (1) | MX353096B (https=) |
| WO (1) | WO2012024616A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2705027T3 (es) | 2010-08-19 | 2019-03-21 | Buck Institute For Age Res | Métodos de tratamiento del deterioro cognitivo leve (DCL) y trastornos relacionados |
| BR112015002309A2 (pt) | 2012-08-07 | 2017-07-04 | Buck Inst Res Aging | formulação de múltiplos componentes para aprimorar a função neurológica |
| CA2899938C (en) | 2013-02-12 | 2021-10-19 | Buck Institute For Research On Aging | Hydantoins that modulate bace-mediated app processing |
| US10369108B2 (en) | 2013-03-15 | 2019-08-06 | Mylan Laboratories, Inc. | Hot melt granulation formulations of poorly water-soluble active agents |
| IL286427B2 (en) | 2014-01-28 | 2024-08-01 | Mayo Found Medical Education & Res | Inhibitors bcl-2 anti-apoptotic protein family members for treatment of non cancer pulmonary disease or an opthalmic disease |
| US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| KR102645633B1 (ko) | 2014-03-21 | 2024-03-11 | 알제온, 인크. | 신경학적 장애를 치료하는 방법 |
| CA2976258C (en) | 2015-02-18 | 2024-02-20 | Buck Institute For Research On Aging | Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau |
| AU2016264228B2 (en) * | 2015-05-18 | 2019-06-13 | Synaptec Development Llc | Galantamine clearance of amyloidß |
| EP4275750B1 (en) * | 2015-09-10 | 2026-05-06 | Alzheon, Inc. | Treatment of alzheimer's disease in a particular patient population |
| CA3007641C (en) | 2015-12-09 | 2023-10-17 | Brandeis University | Dbh inhibitors for treating or preventing memory loss |
| US20180250249A1 (en) * | 2016-02-02 | 2018-09-06 | Alzheon, Inc. | Methods of treating neurodegenerative disorders in a particular population |
| EP3455223B1 (en) | 2016-05-12 | 2023-11-08 | Buck Institute for Research on Aging | Compounds to promote normal processing of app |
| US20210230221A1 (en) | 2017-01-03 | 2021-07-29 | Bioatla, Llc | Protein therapeutics for treatment of senescent cells |
| US11026963B2 (en) | 2018-07-11 | 2021-06-08 | Rubedo Life Sciences, Inc. | Senolytic compositions and uses thereof |
| CN110232679A (zh) * | 2019-05-24 | 2019-09-13 | 潘丹 | 一种阿尔茨海默症遗传生物标志物确定方法及系统 |
| US12521362B2 (en) | 2019-07-25 | 2026-01-13 | Tokyo University Of Science Foundation | Agent for treating, preventing, or improving psychiatric and nervous system disorders or symptoms |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JPS5936675A (ja) | 1982-07-13 | 1984-02-28 | サンド・アクチエンゲゼルシヤフト | 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド |
| ES2217250T3 (es) | 1990-06-15 | 2004-11-01 | Scios Inc. | Mamifero transgenico, no humano que muestra la patologia de formacion amiloides de la enfermedad de alzheimer. |
| ES2236682T5 (es) | 1991-01-21 | 2011-03-31 | Elan Pharmaceuticals, Inc. | Ensayo y modelo para la enfermedad de alzheimer. |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5206264A (en) | 1991-11-04 | 1993-04-27 | Cypros Pharmaceutical Corporation | Use of disulfiram to prevent cardiovascular damage |
| AU671093B2 (en) | 1992-01-07 | 1996-08-15 | Elan Pharmaceuticals, Inc. | Transgenic animal models for alzheimer's disease |
| US5604102A (en) | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
| AU702293B2 (en) | 1993-10-27 | 1999-02-18 | Athena Neurosciences, Inc. | Transgenic animals harboring APP allele having Swedish mutation |
| US5877399A (en) | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
| US5744346A (en) | 1995-06-07 | 1998-04-28 | Athena Neurosciences, Inc. | β-secretase |
| JPH11507538A (ja) | 1995-06-07 | 1999-07-06 | アテナ ニューロサイエンシズ インコーポレイティド | β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ |
| SE9600683D0 (sv) | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
| US6045829A (en) | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
| WO2000003819A1 (en) | 1998-07-17 | 2000-01-27 | The Penn State Research Foundation | Full form roll finishing technique |
| US6331571B1 (en) | 1998-08-24 | 2001-12-18 | Sepracor, Inc. | Methods of treating and preventing attention deficit disorders |
| PL205294B1 (pl) | 1998-09-24 | 2010-03-31 | Upjohn Co | Izolowany lub oczyszczony polipeptyd, oczyszczony lub izolowany polinukleotyd, wektor, wektor ekspresyjny, komórka gospodarza, sposób wytwarzania polipeptydu, sposoby identyfikowania czynnika obniżającego, modulującego lub hamującego aktywność, zastosowanie takiego czynnika, izolowany kwas nukleinowy, obejmujący go wektor i ich zastosowanie, sposoby zmniejszania komórkowego wytwarzania beta amyloidu i zastosowanie antysensownego reagenta |
| US6337328B1 (en) | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
| US6342496B1 (en) | 1999-03-01 | 2002-01-29 | Sepracor Inc. | Bupropion metabolites and methods of use |
| ES2235854T3 (es) | 1999-04-05 | 2005-07-16 | Emisphere Technologies, Inc. | Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos. |
| US20040092511A1 (en) | 1999-12-10 | 2004-05-13 | Billstein Stephan Anthony | Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders |
| US20070059367A1 (en) | 2000-06-06 | 2007-03-15 | Cherukuri S R | Drug Delivery System and Associated Methods |
| US20020115727A1 (en) | 2000-12-04 | 2002-08-22 | Senanayake Chris H. | Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines |
| US20020107244A1 (en) | 2001-02-02 | 2002-08-08 | Howard Harry R. | Combination treatment for depression |
| US20040121010A1 (en) | 2002-10-25 | 2004-06-24 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
| JP4288263B2 (ja) | 2002-10-25 | 2009-07-01 | コレジウム ファーマシューティカル， インク． | ｐ−ヒドロキシ−ミルナシプランの立体異性体およびその使用方法 |
| FR2846559B1 (fr) | 2002-10-31 | 2007-06-15 | Centre Nat Rech Scient | Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle |
| US7148226B2 (en) | 2003-02-21 | 2006-12-12 | Agouron Pharmaceuticals, Inc. | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
| CA2557541C (en) | 2004-02-26 | 2014-12-16 | Aska Pharmaceutical Co., Ltd. | Pyrimidine derivatives |
| US7794403B2 (en) | 2004-04-21 | 2010-09-14 | Mear Holding B.V. | System for measuring pulsatile vascular resistance |
| JP4834837B2 (ja) | 2004-04-30 | 2011-12-14 | 国立大学法人 千葉大学 | 精神神経疾患の治療薬 |
| US8193250B2 (en) * | 2004-10-22 | 2012-06-05 | Mount Sinai School Of Medicine | Compositions and methods for treating alzheimer's disease and related disorders and promoting a healthy nervous system |
| CN101132777A (zh) | 2004-12-20 | 2008-02-27 | 科利吉姆制药公司 | 用于睡眠障碍的药物组合物 |
| EP1844000B1 (en) | 2004-12-23 | 2010-01-27 | Xenoport, Inc. | Serine amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof |
| JP2008536866A (ja) | 2005-04-15 | 2008-09-11 | ボード、オブ、トラスティーズ、オブ、ミシガン、ステイト、ユニバーシティ | アミン作動性医薬組成物および方法 |
| GB0515090D0 (en) | 2005-07-22 | 2005-08-31 | Birmingham Res & Dev Ltd | Novel epilepsy treatment |
| AU2006308889A1 (en) * | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
| CA2644458A1 (en) | 2006-03-01 | 2007-09-07 | Galderma Research & Development | Method of treating inflammatory skin diseases using tropisetron, and pharmaceutical compositions thereof |
| KR101450356B1 (ko) * | 2006-11-24 | 2014-10-15 | 에이씨 이뮨 에스.에이. | 알츠하이머와 같은 아밀로이드 또는 아밀로이드-유사 단백질과 관련된 질환의 치료를 위한 ｎ-(메틸)-1ｈ-피라졸-3-아민, ｎ-(메틸)-피리딘-2-아민 및 ｎ-(메틸)-티아졸-2-아민 유도체 |
| WO2008074896A1 (en) | 2006-12-21 | 2008-06-26 | Prendergast Patrick T | Compositions and methods for treatment of chronic neurological disorders |
| US8586627B2 (en) | 2007-05-03 | 2013-11-19 | Jack L. Arbiser | Honokiol analogs and their use in treating cancers |
| EP2219449A4 (en) | 2007-11-16 | 2010-10-27 | Univ Arizona State | METHOD FOR THE TREATMENT OF EXPOSURE TO DAMAGING |
| CL2007003877A1 (es) | 2007-12-28 | 2008-06-27 | Univ De Concepcion Lab Androma | Composicion farmaceutica que comprende un complejo de inclusion formado por disulfiram y una ciclodextrina; y su uso para el tratamiento de la dependencia de alcohol y cocaina. |
| ES2563061T3 (es) | 2008-04-28 | 2016-03-10 | Zogenix, Inc. | Nuevas formulaciones para el tratamiento de la migraña |
| KR101653707B1 (ko) | 2008-05-29 | 2016-09-02 | 알바니 몰레큘라 리써치, 인크. | 5-ｈｔ3 수용체 조절제, 이의 제조 방법, 및 그의 용도 |
| JP5514827B2 (ja) | 2008-09-25 | 2014-06-04 | バイオランド リミテッド | ４−ｏ−メチルホノキオールを含有するアミロイド関連疾患の治療又は予防用組成物 |
| WO2010041279A2 (en) | 2008-10-08 | 2010-04-15 | V.B. Medicare Pvt. Ltd. | Sustained release drug delivery system |
| US20100099701A1 (en) | 2008-10-20 | 2010-04-22 | Auspex Pharmaceuticals, Inc. | Isoquinolinone modulators of 5-ht3 receptors |
| CN101444508B (zh) | 2008-12-29 | 2010-10-27 | 海南瑞基药物研究有限公司 | 一种注射用托烷司琼制剂及其制备方法 |
| EP2432437A4 (en) | 2009-05-21 | 2012-12-19 | Bionex Pharmaceuticals Llc | TWO- AND ONE-LAYER DOSAGE FORMS |
| US20110003005A1 (en) | 2009-07-06 | 2011-01-06 | Gopi Venkatesh | Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions |
| US9790109B2 (en) * | 2010-04-30 | 2017-10-17 | General Electric Company | Method for sanitizing an electrodeionization device |
| ES2705027T3 (es) | 2010-08-19 | 2019-03-21 | Buck Institute For Age Res | Métodos de tratamiento del deterioro cognitivo leve (DCL) y trastornos relacionados |
| KR101368587B1 (ko) | 2010-12-27 | 2014-03-05 | 주식회사 삼양바이오팜 | 오심 또는 구토 방지용 조성물 |
| EP2508174A1 (en) | 2011-04-06 | 2012-10-10 | Ljiljana Sovic Brkicic | Pharmaceutical composition |
| US8426450B1 (en) | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
| US20150030683A1 (en) | 2012-02-18 | 2015-01-29 | Buck Institute For Research On Aging | Formulations and methods for the treatment or prophylaxis of pre-mci and/or pre-alzheimer's conditions |
-
2011
- 2011-08-19 ES ES11818848T patent/ES2705027T3/es active Active
- 2011-08-19 EP EP11818848.1A patent/EP2605655B1/en active Active
- 2011-08-19 JP JP2013525003A patent/JP6250394B2/ja active Active
- 2011-08-19 DK DK11818848.1T patent/DK2605655T3/en active
- 2011-08-19 WO PCT/US2011/048472 patent/WO2012024616A1/en not_active Ceased
- 2011-08-19 CA CA2808630A patent/CA2808630A1/en not_active Abandoned
- 2011-08-19 MX MX2013001917A patent/MX353096B/es active IP Right Grant
- 2011-08-19 US US13/213,960 patent/US10449177B2/en active Active
- 2011-08-19 AU AU2011291506A patent/AU2011291506B2/en not_active Ceased
- 2011-08-19 BR BR112013003847A patent/BR112013003847A8/pt not_active IP Right Cessation
-
2016
- 2016-08-18 JP JP2016160482A patent/JP2016193944A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DK2605655T3 (en) | 2019-02-04 |
| AU2011291506A1 (en) | 2013-03-14 |
| US20120071468A1 (en) | 2012-03-22 |
| AU2011291506B2 (en) | 2016-07-28 |
| MX2013001917A (es) | 2013-10-25 |
| WO2012024616A1 (en) | 2012-02-23 |
| MX353096B (es) | 2017-12-19 |
| EP2605655B1 (en) | 2018-10-24 |
| JP2013534256A (ja) | 2013-09-02 |
| US10449177B2 (en) | 2019-10-22 |
| CA2808630A1 (en) | 2012-02-23 |
| EP2605655A4 (en) | 2014-01-08 |
| ES2705027T3 (es) | 2019-03-21 |
| JP2016193944A (ja) | 2016-11-17 |
| BR112013003847A2 (pt) | 2016-05-31 |
| EP2605655A1 (en) | 2013-06-26 |
| JP6250394B2 (ja) | 2017-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013003847A8 (pt) | métodos de tratar a deterioração cognitiva moderada (mci) e os distúrbios relacionados | |
| UA109991C2 (xx) | Карбаматні сполуки, їх отримання і застосування | |
| EA201071245A1 (ru) | Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс | |
| EA201992878A1 (ru) | Соединения для лечения болезни хантингтона | |
| NZ729643A (en) | Combination therapy for treating cancer | |
| EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| EA201000603A1 (ru) | ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ | |
| BR112014026703A2 (pt) | inibidores de dna-pk | |
| BR112015014458A2 (pt) | derivados de manose para o tratamento de infecções bacterianas | |
| BR112015001847A2 (pt) | composições e tratamento para doenças e distúrbios nos olhos | |
| BR112015022417A2 (pt) | métodos e composições para inibição de proteínas contendo bromodomínio | |
| EA201590353A1 (ru) | Способы лечения болезни альцгеймера и фармацевтические композиции | |
| EA201190217A1 (ru) | Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение | |
| BR112014021104A2 (pt) | métodos e composições para o tratamento da doença de huntington | |
| MD20150043A2 (ro) | Inhibitori ai histon-demetilazelor | |
| EA201100138A1 (ru) | 4-феноксиметилпиперидины в качестве модуляторов активности gpr119 | |
| BR112015009168A2 (pt) | composto de fórmula estrutural xi, uso de um composto, composição farmacêutica, método de tratamento de uma doença mediada pela pde4 em um sujeito, método de modulação de uma função mediada pela pde4 em um sujeito, método de alcançar um efeito em um paciente e método para inibir a pde4 | |
| EA201590655A1 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
| EA201300471A1 (ru) | Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3 | |
| BR112014018027A8 (pt) | Composto, composição farmacêutica e usos dos mesmos e métodos para aumentar a inclusão de éxon 7 de ame2 em rnam que é transcrito a partir do gene ame2 e para aumentar a quantidade de proteína smn | |
| MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
| MX2015007479A (es) | Tiazolidindionas ahorradoras de receptores activados proliferadores de peroxisoma (ppar) y combinaciones para el tratamiento de enfermedades neurodegenerativas. | |
| EA201200098A1 (ru) | Конденсированные имидазолы и содержащие их композиции, предназначенные для лечения паразитарных заболеваний, таких как, например, малярия | |
| EA201200570A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| BR112012025590A2 (pt) | análogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2529 DE 25-06-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |